Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 20;19(2):1415-1422.
doi: 10.1007/s40200-020-00662-6. eCollection 2020 Dec.

Investigation of the synergistic effect of glimepiride and rosuvastatin on alloxan-induced diabetic rat

Debashish Mondol  1 , Md Nahinul Islam  1 , Sonchita Biswas  1 , Protic Jodder  1 , Samiron Sana  1 , Md Abu Saleh  2 , Md Rafiqul Islam  1
Affiliations

Investigation of the synergistic effect of glimepiride and rosuvastatin on alloxan-induced diabetic rat

Debashish Mondol et al. J Diabetes Metab Disord. .

Abstract

Purpose: Diabetes mellitus is characterized by having a multitude of life-threatening secondary complications, particularly dyslipidemia, which ultimately leads to the development of comorbid diseases, such as cardiovascular diseases. This research work was designed to investigate the synergistic effect of glimepiride (1 mg/kg b.w.) and rosuvastatin (10 mg /kg b.w.) on alloxan-induced diabetic rats having dyslipidemia.

Methods: Diabetes was induced by injecting alloxan (120 mg/kg b.w.) intraperitoneally. The experiment was conducted to determine the level of blood glucose, HbA1c, lipid profile, and body weight variation of rats.

Results: This study's outcomes suggested that the combination therapy showed more statistically significant effect on blood glucose level, HbA1c level, lipid profile, and body weight variation than any single therapy. While the glimepiride monotherapy showed a statistically considerable effect on blood glucose level, HbA1c level, and body weight variation, the rosuvastatin treated group gave statistically non-significant effect on these parameters except body weight variation, which was found as downward trend. In addition, the rosuvastatin treated group showed a healthy lipid profile compared to glimepiride treated group.

Conclusions: Concluding the results of this study, it can be said that the treatment of glimepiride in combination with rosuvastatin may be more efficacious than monotherapy for preventing diabetes in rats with dyslipidemia.

Keywords: Alloxan; Cardiovascular disease; Combination therapy; Diabetes; Dyslipidemia; Hyperglycemia.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestThe authors declare that there is no conflict of interest regarding the publication of this paper.

Figures

Fig. 1
Fig. 1
Observing effects of combination therapy and monotherapy on HbA1c Level. ††† = p < 0.001 vs Group-NC and *** = p < 0.001 vs Group-DC
Fig. 2
Fig. 2
Observing effect of combination therapy and monotherapy on serum TG concentration. ††† = p < 0.001 vs Group-NC and ** = p < 0.01 and *** = p < 0.001 vs Group-DC
Fig. 3
Fig. 3
Observing effect of combination therapy and monotherapy on serum TC concentration †† = p < 0.01 vs Group-NC and *** = p < 0.001 vs Group-DC
Fig. 4
Fig. 4
Observing effect of combination therapy and monotherapy on serum LDL-C concentration. † = p < 0.05 vs Group-NC and ** = p < 0.01 and *** = p < 0.001 vs Group-DC
Fig. 5
Fig. 5
Observing effect of combination therapy and monotherapy on serum HDL-C concentration. * = p < 0.05; ** = p < 0.01 vs Group-DC
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kennedy MSN, Masharani U. Pancreatic Hormones & Antidiabetic Drugs. In: Katzung BG, editor. Basic Clin Pharmacol a LANGE Med B. 14th ed. McGraw-Hill Education; 2018. p. 747–771.
    1. Philipson LH, Steiner DF. Pas de deux or more: The sulfonylurea receptor and K+ channels. Science. 1995;268:372–3. - PubMed
    1. Massi-Benedetti M. Glimepiride in type 2 diabetes mellitus: A review of the worldwide therapeutic experience. Clin Ther. 2003;25:799–816. - PubMed
    1. Jeng C-Y, Hollenbeck CB, Wu MS, Foley JE, Chen Y-DI, Reaven GM. Changes in carbohydrate metabolism in association with glipizide treatment of type 2 diabetes. Diabet Med. 1991;8:32–39. doi: 10.1111/j.1464-5491.1991.tb01513.x. - DOI - PubMed
    1. Kolterman OG, Gray RS, Shapiro G, Scarlett JA, Griffin J, Olefsky JM. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes. 1984;33:346–354. doi: 10.2337/diab.33.4.346. - DOI - PubMed

LinkOut - more resources